Correspondingly, ACTL6A protein levels examined by western blotting and immunohistochemical staining in a cohort of glioma and non-neoplastic brain tissue samples from our own institution were increased in high-grade gliomas (WHO III–IV; n = 12), relative to normal brain tissues (n = 4) and low-grade gliomas (WHO II; n = 4; Fig. 1b). Here, ACTL6A is linked to central nervous system cancer.